CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in CASI Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −2 vs. Q2 2024
- Shares held
- 1.32M
- +970.7K (+275.8%) vs. Q2 2024
- Total value
- $8.14M
- +$6.20M (+320.7%) vs. Q2 2024
- New holders
- 3
- 4 more added
- Sold out
- 5
- 2 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CASIF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $17 |
| Q1 2026 | 1 | $25 |
| Q4 2025 | 16 | $1.06M |
| Q3 2025 | 22 | $4.33M |
| Q2 2025 | 24 | $2.66M |
| Q1 2025 | 23 | $5.93M |
| Q4 2024 | 22 | $7.52M |
| Q3 2024 | 20 | $8.14M |
| Q2 2024 | 23 | $1.94M |
| Q1 2024 | 20 | $920.0K |
| Q4 2023 | 18 | $1.99M |
| Q3 2023 | 19 | $882.6K |
| Q2 2023 | 19 | $1.12M |
| Q1 2023 | 21 | $2.15M |
| Q4 2022 | 1 | $179 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding CASI Pharmaceuticals, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VR Adviser, LLC | 987,259 | $6.08M | 0.32% | +875,573+784.0% | Added |
| Wellington Shields Capital Management, LLC | 89,217 | $549.6K | 0.10% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 64,835 | $399.4K | 0.07% | +56,595+686.8% | Added |
| Wellington Shields & Co., LLC | 43,091 | $265.4K | 0.08% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 41,500 | $255.6K | 0.00% | +700+1.7% | Added |
| Woodline Partners LP | 30,532 | $188.1K | 0.00% | +30,532 | New |
| Citadel Advisors LLC | 22,714 | $135.4K | 0.00% | +22,714 | New |
| Geode Capital Management, LLC | 19,363 | $115.4K | 0.00% | −2,858−12.9% | Reduced |
| UBS Group AG | 14,681 | $90.4K | 0.00% | +3,360+29.7% | Added |
| Royal Bank of Canada | 6,900 | $43.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,440 | $8.87K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 506 | $3.12K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 296 | $1.82K | 0.00% | +296 | New |
| West Paces Advisors Inc. | 100 | $616 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 50 | $298 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 28 | $172 | 0.00% | −25−47.2% | Reduced |
| Northwestern Mutual Wealth Management Co | 13 | $80 | 0.00% | 00.0% | Unchanged |
| Colonial Trust Co | 11 | $68 | 0.00% | 00.0% | Unchanged |
| Trust Co of Vermont | 10 | $62 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 8 | $49 | 0.00% | 00.0% | Unchanged |
| Howland Capital Management LLC | 0 | $0 | 0.00% | −15,072−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,042−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Kozak & Associates, Inc. | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |